To date in clinical practice, besides PD-L1 expression that is actually use to drive the choice of immunotherapy regimens in non-small cell lung cancer that lacks a driver mutation, there is no strong predictive factor of immune checkpoint blockade. This evidence concerns the gene CD274 and non-small cell lung carcinoma.